Apellis Pharmaceuticals (APLS) PT Lowered to $69 at BMO Capital, Overall Data 'Should Still be Enough'
Tweet Send to a Friend
BMO Capital analyst Matthew Luchini lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $69.00 (from $89.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
